Soligenix, Inc. (简称Soligenix) 近日公布,其研发的药物Sgx945已获得英国药品和保健品监管局(MHRA)颁发的“前景看好的创新药物”(Promising Innovative Medicine, PIM)资格认定。这一认定标志着该药物在治疗严重疾病方面展现出显著潜力,并有望加速其在英国的开发和审批进程。
Soligenix, Inc. (简称Soligenix) 近日公布,其研发的药物Sgx945已获得英国药品和保健品监管局(MHRA)颁发的“前景看好的创新药物”(Promising Innovative Medicine, PIM)资格认定。这一认定标志着该药物在治疗严重疾病方面展现出显著潜力,并有望加速其在英国的开发和审批进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.